Immunotherapy for nonsmall cell lung cancer: a new therapeutic algorithm
- 6 February 2020
- journal article
- editorial
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 55 (2) , 1901907
Abstract
Immunotherapy is a new approach for the treatment of lung cancer with impressive long-term resultshttp://bit.ly/35GVzAnKeywords
This publication has 32 references indexed in Scilit:
- Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 StudyJournal of Clinical Oncology, 2018
- Les inhibiteurs des freins immunitaires (anticorps anti-PD1 et anti-PD-L1), une nouvelle arme thérapeutique dans les cancers bronchiques non à petites cellulesRevue des Maladies Respiratoires, 2018
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trialThe Lancet, 2017
- Lung cancer: current therapies and new targeted treatmentsThe Lancet, 2017
- Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet Oncology, 2016
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialThe Lancet, 2016
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1Clinical Cancer Research, 2012
- Enhancement of Antitumor Immunity by CTLA-4 BlockadeScience, 1996